How a Chinese HPLC System Consolidates Two Diagnostic Workflows

H100 Hemoglobin Analyzer (HbA1c HPLC System) – High-Precision Diabetes & Thalassemia Testing

The H100 Hemoglobin Analyzer is a fully automated HPLC system that runs both HbA1c tests for diabetes monitoring and thalassemia screening on the same hardware. Its dual-mode architecture — switchable via software — eliminates the need for separate instruments in medium-to-high-volume labs.

Specifications reveal a machine built for throughput: HbA1c results in 96 seconds per test, a sample loader handling up to 110 positions, and automated inversion mixing to reduce variance. The system stores 20,000 results locally and supports NGSP and IFCC certification standards, aligning with international reporting protocols.

The variant detection feature — branded as V-win reporting — automatically flags abnormal hemoglobin variants during routine runs. This turns every HbA1c test into a potential thalassemia screen, a capability especially relevant in regions with high carrier prevalence.

From a procurement perspective, the H100 reduces capital expenditure. Instead of acquiring separate glycohemoglobin and hemoglobin electrophoresis systems, labs get both functions in one chassis, with a common reagent supply and workflow. The Linux-based interface and one-click mode switching lower training overhead.

China’s diagnostic manufacturing ecosystem has matured to the point where it can deliver NGSP/IFCC-certified HPLC platforms at a price point that undercuts legacy suppliers. The H100 is a concrete example of how domestic OEMs are capturing the mid-tier clinical lab market — not through novelty, but through consolidation of proven technologies.

For hospital networks and diagnostic chains evaluating lab efficiency, the calculus is straightforward: one operator, one instrument, two test menus.

Why it matters:
The H100 compresses two capital-intensive workflows into a single purchase. For buyers in cost-sensitive markets, it offers a path to NGSP-certified HbA1c testing without compromising on thalassemia screening coverage. For suppliers, it signals a shift toward multi-parameter platforms as the default lab configuration.

View Product →